Other equities analysts have also recently issued reports about the stock. JPMorgan Chase & Co. set a GBX 7,000 ($91.47) price objective on shares of Reckitt Benckiser Group and gave the stock a buy rating in a research report on Monday, July 23rd. Cfra set a GBX 7,500 ($98.00) price objective on shares of Reckitt Benckiser Group and gave the stock a buy rating in a research report on Monday, July 30th. Jefferies Financial Group set a GBX 6,800 ($88.85) price objective on shares of Reckitt Benckiser Group and gave the stock a neutral rating in a research report on Wednesday, August 1st. Shore Capital restated a hold rating on shares of Reckitt Benckiser Group in a report on Friday, July 27th. Finally, Kepler Capital Markets set a GBX 6,300 ($82.32) price target on shares of Reckitt Benckiser Group and gave the company a neutral rating in a report on Friday, July 27th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of GBX 7,115.48 ($92.98).
Reckitt Benckiser Group stock traded down GBX 127 ($1.66) during mid-day trading on Thursday, hitting GBX 6,464 ($84.46). The company’s stock had a trading volume of 534,508 shares, compared to its average volume of 1,720,000. Reckitt Benckiser Group has a twelve month low of GBX 5,562 ($72.68) and a twelve month high of GBX 8,110.43 ($105.98).
Reckitt Benckiser Group Company Profile
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Recommended Story: How Important is Technical Analysis of Stocks
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.